Cargando…
SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience
BACKGROUND AND OBJECTIVES: The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in genotype 3 (GT3) with...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519817/ https://www.ncbi.nlm.nih.gov/pubmed/31091254 http://dx.doi.org/10.1371/journal.pone.0215783 |
_version_ | 1783418670058307584 |
---|---|
author | Mangia, Alessandra Piazzolla, Valeria Giannelli, Anna Visaggi, Egidio Minerva, Nicola Palmieri, Vincenzo Carraturo, Immacolata Potenza, Domenico Napoli, Nicola Lauletta, Gianfranco Tagarielli, Vincenzo Santoro, Rosanna Piccigallo, Ernesto De Gioia, Sergio Chimenti, Angelo Cuccorese, Giuseppe Metrangolo, Antonio Mazzola, Michele Agostinacchio, Ernesto Mennea, Giuseppe Sabbà, Carlo Cela, Marina Copetti, Massimiliano Losappio, Ruggiero |
author_facet | Mangia, Alessandra Piazzolla, Valeria Giannelli, Anna Visaggi, Egidio Minerva, Nicola Palmieri, Vincenzo Carraturo, Immacolata Potenza, Domenico Napoli, Nicola Lauletta, Gianfranco Tagarielli, Vincenzo Santoro, Rosanna Piccigallo, Ernesto De Gioia, Sergio Chimenti, Angelo Cuccorese, Giuseppe Metrangolo, Antonio Mazzola, Michele Agostinacchio, Ernesto Mennea, Giuseppe Sabbà, Carlo Cela, Marina Copetti, Massimiliano Losappio, Ruggiero |
author_sort | Mangia, Alessandra |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in genotype 3 (GT3) with compensated and is recommended in decompensated cirrhosis. Real-life results with SOF/VEL are limited. To evaluate efficacy and safety in a large real-world-cohort including patients with different GTs and various fibrosis stages. DESIGN: In total, 1429 patients were treated with SOF/VEL 400/100 mg for 12 weeks in the Puglia registry between June 2017 and May 2018. 1319 (92.3%) reached week 12 post-treatment (SVR12) at the moment. Only 41 received RBV. Diagnosis of cirrhosis was based on transient elastography and/or APRI or FIB-4 scores. Sensitivity analysis in the population including all patients except non virological failure was conducted. Primary efficacy endpoint was the percentage of patients with SVR12. RESULTS: Patients’ mean age was 63.8 years, 42.3% had GT1. The majority were naïve and 735 (55.5%) F0/F2. Of the remaining 587, 282 had cirrhosis. SVR12 was 98.5%, 98.0% in GT1, 99.4% in GT2, 97.1% in GT3, 100% in GT4. Overall, SVR12 by sensitivity analysis was 99.4%; 99.7% among F0-F1. Among 218 PWID, SVR12 was 94.5%. Discontinuation rates were 3.7% among PWID and 0.7% among non-PWID (p = 0.004). CONCLUSIONS: SOF/VEL treatment of chronic HCV infection reaches very high cure rates in a variety of patients; including those with F0/F1 and PWID. |
format | Online Article Text |
id | pubmed-6519817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-65198172019-05-31 SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience Mangia, Alessandra Piazzolla, Valeria Giannelli, Anna Visaggi, Egidio Minerva, Nicola Palmieri, Vincenzo Carraturo, Immacolata Potenza, Domenico Napoli, Nicola Lauletta, Gianfranco Tagarielli, Vincenzo Santoro, Rosanna Piccigallo, Ernesto De Gioia, Sergio Chimenti, Angelo Cuccorese, Giuseppe Metrangolo, Antonio Mazzola, Michele Agostinacchio, Ernesto Mennea, Giuseppe Sabbà, Carlo Cela, Marina Copetti, Massimiliano Losappio, Ruggiero PLoS One Research Article BACKGROUND AND OBJECTIVES: The pangenotypic single tablet regimen of NS5B inhibitor sofobuvir (SOF) and NS5A inhibitor velpatasvir (VEL) is advised for 12 weeks in HCV-infected patients including those with compensated cirrhosis. Addition of ribavirin (RBV) may be considered in genotype 3 (GT3) with compensated and is recommended in decompensated cirrhosis. Real-life results with SOF/VEL are limited. To evaluate efficacy and safety in a large real-world-cohort including patients with different GTs and various fibrosis stages. DESIGN: In total, 1429 patients were treated with SOF/VEL 400/100 mg for 12 weeks in the Puglia registry between June 2017 and May 2018. 1319 (92.3%) reached week 12 post-treatment (SVR12) at the moment. Only 41 received RBV. Diagnosis of cirrhosis was based on transient elastography and/or APRI or FIB-4 scores. Sensitivity analysis in the population including all patients except non virological failure was conducted. Primary efficacy endpoint was the percentage of patients with SVR12. RESULTS: Patients’ mean age was 63.8 years, 42.3% had GT1. The majority were naïve and 735 (55.5%) F0/F2. Of the remaining 587, 282 had cirrhosis. SVR12 was 98.5%, 98.0% in GT1, 99.4% in GT2, 97.1% in GT3, 100% in GT4. Overall, SVR12 by sensitivity analysis was 99.4%; 99.7% among F0-F1. Among 218 PWID, SVR12 was 94.5%. Discontinuation rates were 3.7% among PWID and 0.7% among non-PWID (p = 0.004). CONCLUSIONS: SOF/VEL treatment of chronic HCV infection reaches very high cure rates in a variety of patients; including those with F0/F1 and PWID. Public Library of Science 2019-05-15 /pmc/articles/PMC6519817/ /pubmed/31091254 http://dx.doi.org/10.1371/journal.pone.0215783 Text en © 2019 Mangia et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Mangia, Alessandra Piazzolla, Valeria Giannelli, Anna Visaggi, Egidio Minerva, Nicola Palmieri, Vincenzo Carraturo, Immacolata Potenza, Domenico Napoli, Nicola Lauletta, Gianfranco Tagarielli, Vincenzo Santoro, Rosanna Piccigallo, Ernesto De Gioia, Sergio Chimenti, Angelo Cuccorese, Giuseppe Metrangolo, Antonio Mazzola, Michele Agostinacchio, Ernesto Mennea, Giuseppe Sabbà, Carlo Cela, Marina Copetti, Massimiliano Losappio, Ruggiero SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title_full | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title_fullStr | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title_full_unstemmed | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title_short | SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience |
title_sort | svr12 rates higher than 99% after sofosbuvir/velpatasvir combination in hcv infected patients with f0-f1 fibrosis stage: a real world experience |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519817/ https://www.ncbi.nlm.nih.gov/pubmed/31091254 http://dx.doi.org/10.1371/journal.pone.0215783 |
work_keys_str_mv | AT mangiaalessandra svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT piazzollavaleria svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT giannellianna svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT visaggiegidio svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT minervanicola svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT palmierivincenzo svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT carraturoimmacolata svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT potenzadomenico svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT napolinicola svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT laulettagianfranco svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT tagariellivincenzo svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT santororosanna svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT piccigalloernesto svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT degioiasergio svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT chimentiangelo svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT cuccoresegiuseppe svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT metrangoloantonio svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT mazzolamichele svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT agostinacchioernesto svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT menneagiuseppe svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT sabbacarlo svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT celamarina svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT copettimassimiliano svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience AT losappioruggiero svr12rateshigherthan99aftersofosbuvirvelpatasvircombinationinhcvinfectedpatientswithf0f1fibrosisstagearealworldexperience |